Aim: Vemurafenib, a BRAF kinase inhibitor, is effective and safe in MM with BRAF V600 mutation. We describe the ad interim analysis of the Italian cohort of the global safety study on vemurafenib. Methods: Patients with untreated or previously treated BRAFV600 MM received oral vemurafenib 960 mg twice daily until progression or toxicity. Results: Overall, 385 patients were evaluated; 135 received prior systemic chemotherapy (35%) and 44 (11%) ipilimumab. Forty-eight patients had stage M1a disease, 53 M1b and 280 M1c. Median follow-up was 11.5 mos (95% CI 11.2-11.8). Three hundred and thirty patients (86%) reported at least one adverse event (AE). Common AEs included rash (21%), arthralgia (25%), asthenia (14%), alopecia (13%), nausea (12%). Squamous cell carcinoma was diagnosed in 8 patients (2.1%), keratoacanthoma in 9 (2.3%). Sixteen severe AEs were reported; among these, 3 were related to vemurafenib. Response rate was assessed in 332 patients: 4.2% (n = 14) showed a complete response, 26.2% (n = 87) a partial response and 54.5% (n = 181) stable disease. Median progression free survival (PFS) and overall survival (OS) were 5.9 mos (95% CI: 5.4-6.8) and 16.3 mos (13.4-not reached), respectively. Furthermore, 21.5% of patients (n = 83) had brain metastasis (BM). In this subgroup, median PFS was 4.3 mos (3.6-5.4) and OS was 7.6 mos (6.0-11.1). In patients without BM the median PFS was 6.5 mos (5.7-8.0) and OS was not reached (16.3-not reached). Results according to disease stage at baseline are reported in Table; 146 patients (37.9%) received vemurafenib beyond progression. Conclusions: Vemurafenib appears safe and active in a population of Italian patients with BRAFV600 mutated MM who are representative of routine clinical practice.
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